ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / DNTH / options
TVTX (52) PTCT (63) ERAS (33) EWTX (41) ⌘ Pro Terminal β†’

Dianthus Therapeutics Inc. (DNTH) Options Positioning, Max Pain & Unusual Sweeps

$82.25 -0.16% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $82.07

Dianthus Therapeutics Inc. (DNTH) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $4.61B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DNTH Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is DNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Dianthus Therapeutics Inc. (NASDAQ: DNTH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $82.25 (-0.16% 1D, market cap $4.61B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, DNTH ranks #477 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does DNTH compare to TVTX and PTCT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DNTH carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -30.7%. By comparison, TVTX (Travere Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DNTH?
β–Ό

Per DNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001690585), Dianthus Therapeutics Inc. generated $2.0M in revenue (-67.3% YoY), -$162.3M in net income, and -$129.2M in free cash flow against $530.9M in total assets and $16.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $82.07 (-0.22%)🧬 Dilution Drag (+1.64% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (39/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510039
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D-
Cash (9)Whales (8)SEC (11)Macro (5)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-8.5% Base Target
$124 Bull$75 Base$59 Bear
πŸ“¬ FREE DNTH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for DNTH)Realized 20D OHLCV Swing Band: Β±9.4%
Deterministic 5-Pillar Attribution (39/100 Composite)
πŸ” WHY DNTH SCORES 39/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (46.8) create a -15 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
31
Grade E$74.76+4.5% Next Q
Q2 (-2Q)
34
Grade E$78.10+5.4% Next Q
Q3 (-1Q)
36
Grade E$82.31-0.1% Next Q
Current
39
Grade D-$82.25-7.6% Hist 90D Ξ±
Trajectory: E (31) β†’ D- (39)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a DNTH Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While DNTH currently carries a cautious 39/100 (D-) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($91.05) and Max Pain ($86.36) forces dealer call-delta covering toward $123.77.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DNTHβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œDNTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±9.4%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DNTH)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DNTH.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DNTH)

  • βœ“Walkthrough of DNTH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
DNTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.94%πŸ“ HORIZONTAL RANGE
2026-11-03O $82.70H $82.70L $82.25C $82.25VOL 496.9K
RES: $137.4SUP: $65.05SMA50: $91.05SMA200: $85.60
$122.8$102.4$81.89$61.43$40.97RES $137.4SUP $65.05$82.252026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ DNTH Butterfly Map β†’ + Track DNTH β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.5%/yr Implied 5Y Growth

vs. -67.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DNTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DNTH)

Health Care Rank #477 of 1015 βš”οΈ TVTX vs DNTH Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (DNTH vs. TVTX, PTCT, ERAS, EWTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Dianthus Therapeutics Inc. (DNTH) ranks #477 by composite RQD confidence (39/100, grade D-) and #168 by equity capitalization ($4.61B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and β€” gross margin. PTCT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with DNTH at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DNTH ACTIVE
Dianthus Therapeutics Inc.
D- 39/100 β€” β€” -30.7% -0.16% $4.61B Benchmark Subject
TVTX
Travere Therapeutics Inc.
D+ 52/100 β€” 96.0% -13.0% -2.24% $4.75B /tvtx-vs-dnth β†’
PTCT
PTC Therapeutics Inc.
C 63/100 7.9x β€” 85.0% +1.52% $5.01B /ptct-vs-dnth β†’
ERAS
Erasca Inc.
E 33/100 β€” β€” -35.0% -2.09% $5.02B /eras-vs-dnth β†’
EWTX
Edgewise Therapeutics Inc.
D- 41/100 β€” β€” -31.9% -2.03% $4.22B /ewtx-vs-dnth β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001690585 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dianthus Therapeutics Inc. (DNTH) reported GAAP revenue of $2.0M (-67.3% vs. FY2024 revenue of $6.2M , and -28.0% cumulative change since FY2023) , GAAP net income of -$162.3M, operating cash flow of -$129.1M, and free cash flow of -$129.2M (-64.6% YoY). On the balance sheet, DNTH closed FY2025 with $530.9M in total assets against $16.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.0M -$162.3M -$129.1M -$129.2M $530.9M $16.9M
FY2024 (FY) 2024-12-31 $6.2M -$85.0M -$78.2M -$78.5M $374.0M $9.7M
FY2023 (FY) 2023-12-31 $2.8M -$43.5M -$36.9M -$37.0M $2.54B $595.3M

3. DNTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Dianthus Therapeutics Inc. (NASDAQ: DNTH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $82.25 (-0.16% 1D, market cap $4.61B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, DNTH ranks #477 in composite RQD confidence.

How does DNTH compare to TVTX and PTCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DNTH carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -30.7%. By comparison, TVTX (Travere Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DNTH?

Per DNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001690585), Dianthus Therapeutics Inc. generated $2.0M in revenue (-67.3% YoY), -$162.3M in net income, and -$129.2M in free cash flow against $530.9M in total assets and $16.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DNTH trading relative to its 50-day, 200-day, and 52-week technical levels?

DNTH last traded at $82.25 (-0.16% on volume of 837,834 shares), positioning the stock -9.67% below its 50-day simple moving average ($91.05) and -3.91% below its 200-day simple moving average ($85.60). Across its 52-week range of $32.28 to $117.88, DNTH sits at the 58.4% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±9.4% ($74.52 to $89.98).

Direct Sub-Reports: DNTH RQD Cockpit DNTH 12M Forecast DNTH Earnings & Move DNTH Dividends & DRIP DNTH Insiders & 13F DNTH Whale Options DNTH Profit Sankey DNTH News & Why
ROARABLE RATING BRIEF β€’ RQD 39/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

DNTH β€” Dianthus Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Dianthus Therapeutics Inc. (DNTH) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $82.25 (-0.16% 1D, market capitalization $4.61B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -30.7%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -2.79%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (11/20): Incorporates a 1.08x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 4/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Dianthus Therapeutics Inc. (DNTH) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The company's products, customers, and revenue model are not described in the source data. Reported revenue was $2.0M in FY 2025, $6.2M in FY 2024, and $2.8M in FY 2023. Market capitalization is $4.6B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Dianthus Therapeutics Inc. (DNTH) reported $2.0M in annual revenue (up from $6.2M in FY2024, -67.3% YoY) and -$162.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.8M revenue, -$43.5M net income) through FY2025, DNTH scaled operating cash flow to -$129.1M and free cash flow to -$129.2M, backed by $530.9M in total assets against $16.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.79% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $32.28 – $117.88 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), DNTH carries a macro regime beta of 1.08 and gross margin of β€”.

  • Key Question #1: Can DNTH sustain or expand its -60.0% operating margin and -30.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$129.2M, how will capital allocation balance growth reinvestment against $16.9M in total debt?
  • Key Question #3: How sensitive is DNTH's 20.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

DNTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dianthus Therapeutics Inc. (DNTH) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to DNTH Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DNTH Bull vs. Bear Conversation Board β€” What's Your Call at $82.25?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DNTH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DNTH:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $105.45 (+28.0%)
πŸ“Œ Pinned Debate

Low leverage (Debt/Equity 0.03) and a forward P/E of 20 give the balance sheet and forward earnings expectations some support despite h

Picked up a starter position in DNTH in my $100K Virtual Cash book at $82.38. Low leverage (Debt/Equity 0.03) and a forward P/E of 20 give the balance sheet and forward earnings expectations some support despite heavy losses.. Trading inside a $32.42–$117.88 52-week range with -2.79% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

CapAlloc_Nerd πŸ‚ BULL

@MultipleCompression Fair point on 20.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $64.26 (-22.0%)
Spot @ $82.38

ROIC of -30.7%, FCF of -$129.2M in FY 2025, and negative operating margin of -60% show the cash engine is consuming capital rather than

Careful chasing DNTH at $82.38. ROIC of -30.7%, FCF of -$129.2M in FY 2025, and negative operating margin of -60% show the cash engine is consuming capital rather than generating it.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $64.26 on multiple compression.

LIVE TAPE